Nimbus is back for more, raising $210M to fuel pipeline seven months after $4B Takeda deal

in Portfolio News

What kind of biotech company returns billions to its investors without ever opening a lab, commercializing a drug, or going public with an IPO?

Nimbus Therapeutics. After raising $125 million just a year ago and selling a still-experimental pill to Takeda Pharmaceutical in a deal earlier this year that could be worth as much as$6 billion, the small Boston-based biotech is back for more.

View the article
Investing in Women Code Logo

We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.